Randomized, double-blind, multicenter trial comparing two doses of Arzoxifene (LY353381) in hormone-sensitive advanceor metastitic breast cancer patients | Charles Explorer

Randomized, double-blind, multicenter trial comparing two doses of Arzoxifene (LY353381) in hormone-sensitive advanceor metastitic breast cancer patients

Publication at Faculty of Physical Education and Sport |

2003

Abstract

Arzoxifene, breast cancer, study

Person